AU2003265961A1 - Use of histamine h4 receptor modulators for the treatment of allergy and asthma - Google Patents

Use of histamine h4 receptor modulators for the treatment of allergy and asthma Download PDF

Info

Publication number
AU2003265961A1
AU2003265961A1 AU2003265961A AU2003265961A AU2003265961A1 AU 2003265961 A1 AU2003265961 A1 AU 2003265961A1 AU 2003265961 A AU2003265961 A AU 2003265961A AU 2003265961 A AU2003265961 A AU 2003265961A AU 2003265961 A1 AU2003265961 A1 AU 2003265961A1
Authority
AU
Australia
Prior art keywords
histamine
receptor
compound
modulator
chemotaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003265961A
Other languages
English (en)
Inventor
Pragnya J. Desai
Paul J. Dunford
Claudia L. Hofstra
Lars Karlsson
Wai-Ping Leung
Ping Ling
Robin L. Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2003265961A1 publication Critical patent/AU2003265961A1/en
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003265961A 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma Abandoned AU2003265961A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40873602P 2002-09-06 2002-09-06
US60/408,736 2002-09-06
PCT/US2003/027943 WO2004021999A2 (fr) 2002-09-06 2003-09-05 Utilisation de modulateurs du récepteur h4 de l'histamine pour le traitement des allergies et de l'asthme

Publications (1)

Publication Number Publication Date
AU2003265961A1 true AU2003265961A1 (en) 2004-03-29

Family

ID=31978667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003265961A Abandoned AU2003265961A1 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Country Status (6)

Country Link
EP (1) EP1545596A4 (fr)
JP (1) JP2006510590A (fr)
AU (1) AU2003265961A1 (fr)
CA (1) CA2497788A1 (fr)
MX (1) MXPA05002577A (fr)
WO (1) WO2004021999A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671972A1 (fr) * 2004-11-24 2006-06-21 Pfizer Limited Dérivés d' octahydropyrrolo[3,4-c]pyrrole
JP2008520644A (ja) * 2004-11-24 2008-06-19 ファイザー・インク オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
EP2001480A4 (fr) 2006-03-31 2011-06-15 Abbott Lab Composés d'indazole
EP2298772A1 (fr) * 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Composés hétérocycliques condenseé
KR100954138B1 (ko) * 2007-12-31 2010-04-20 부산대학교 산학협력단 지방조직 유래 줄기세포를 함유하는 알레르기 비염 또는천식 예방 및 치료제
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
JP2012102017A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc インドール化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259513A1 (en) * 2000-05-05 2001-11-20 Wyeth Human histamine h4 receptor
CA2410734A1 (fr) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Adn codant pour un recepteur de l'histamine de mammifere de sous-type h4
GB0101223D0 (en) * 2001-01-17 2001-02-28 Pfizer Ltd Histamine receptor antagonists
WO2002072548A2 (fr) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Composes heterocycliques
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
PL375964A1 (en) * 2002-09-06 2005-12-12 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
WO2004022060A2 (fr) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Composes heterocycliques

Also Published As

Publication number Publication date
WO2004021999A3 (fr) 2004-10-07
WO2004021999A2 (fr) 2004-03-18
CA2497788A1 (fr) 2004-03-18
EP1545596A2 (fr) 2005-06-29
JP2006510590A (ja) 2006-03-30
EP1545596A4 (fr) 2005-12-28
MXPA05002577A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
Kirby et al. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus
US20040127395A1 (en) Use of histamine H4 receptor modulators for the treatment of allergy and asthma
Hu et al. Calcium transient evoked by TRPV1 activators is enhanced by tumor necrosis factor-α in rat pulmonary sensory neurons
US7195879B2 (en) Method for identifying modulators of NAv ion channels
AU2003265961A1 (en) Use of histamine h4 receptor modulators for the treatment of allergy and asthma
Gatti et al. Mechanisms of fever and febrile seizures: putative role of the interleukin-1 system
US20040105856A1 (en) Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
EP1572133B1 (fr) Methode d'identification de modulateurs du recepteur de l'orexine 2 humain
WO2004078920A2 (fr) Methode permettant d'induire une mort cellulaire selective dans des cellules cancereuses par activation des canaux potassiques actives par le calcium (kca)
US20240173290A1 (en) Novel use
CN109793730B (zh) 苯并吡喃闭环查尔酮结构类型雄激素受体拮抗剂及其应用
Zheng Canonical transient receptor potential channels as novel targets for antiepileptic drugs
US20030133931A1 (en) Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
US20220273751A1 (en) Gpcr heteromer inhibitors and uses thereof
US20230220037A1 (en) Novel use
US20030171545A1 (en) Novel Protein
CN111170943B (zh) 苯并[f]环戊烷并[c]喹啉衍生物及其应用
TW202124418A (zh) 壞死性凋亡調節劑、篩選方法及醫藥組成物
WO2024013052A1 (fr) Nouvelle utilisation
Wu et al. Unconventional Activation of IRE1 Enhances TH17 Responses and Promotes Airway Neutrophilia
Salvatierra The role of Nav1. 9 and Nav1. 1 in somatosensory perception
Hine Characterization of Novel Cannabinoid Receptor 2-Selective Agonists at the Biochemical and Cellular Levels: Leads for Therapeutic Agents
Jürgens β2 adrenergic receptor desensitization through chronic stimulation of Natural Killer cells
Fabbrini ENDOCRINE, METABOLIC and PSYCHIATRIC SCIENCES
JPWO2002057782A1 (ja) 新規スクリーニング方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO JANSSEN PHARMACEUTICA N.V.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period